Download full report with analyst certification and important disclosures
Nov 23 2020, 11:45 GMT
Immunocore has announced positive phase III data for its uveal melanoma study, hitting the primary endpoint – which is the key marker reviewed by regulators. Based on this data, we think the therapy could be approved and commercially launched in 2021. From a Malin perspective, this important milestone for one of its key assets may increase the chances of a cash exit as the data could be supportive of an Immunocore IPO.
Nov 23 2020, 11:45 GMT